The efficacy of ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study

Niv, Eva; Naftali, Timna; Hallak, Ron; Vaisman, Nachum

doi:10.1016/j.clnu.2005.06.001

Cited by 166 publications

(134 citation statements)

References 23 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Lactobacillus reuteri is, nonetheless, the only strain in these mechanistic studies that has been investigated in a clinical trial, as well and in this case without success. 61 Taken together, our findings demonstrate that a probiotic combination of L. rhamnosus GG, L. rhamnosus Lc705, P. freudenreichii ssp. shermanii JS and B. breve Bb99 can be detected in the GI tract of adult IBS patients.…”

Section: Discussionsupporting

confidence: 61%

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome

Kajander

Krogius-Kurikka

Rinttilä

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome

Kajander

Krogius-Kurikka

Rinttilä

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Other lactobacilli strains were used only in single trials, such as Lactobacillus brevi, 90 L. acidophilus, 56,100 Lactobacillus reuteri, 103 Lactobacillus rhamnosus GG, 107 and Lactobacillus casei (CLR35).…”

Section: Bacterial Strainsmentioning

confidence: 99%

Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

Mazurak

Broelz²,

Storr

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsDespite numerous randomized clinical trials and meta-analyses, there is no increased evidence for the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). We review this evidence, identify and analyse the reasons for this lack of evidence and propose methodological improvements for future studies. MethodsBased on a literature search, we identified 56 papers that matched the purpose of our analyses. Twenty-seven studies used multi-species bacterial preparations and 29 used single-strain probiotics. They were analysed regarding patients included, treatment duration, probiotic dosage, and outcome measures. ResultsTrials in both groups suffered from heterogeneity with respect to probiotic concentration, duration of treatment, and other methodological issues (crossover design and underpowered studies). This heterogeneity did not allow the application of a meta-analytic approach and a systematic review was therefore performed instead. Multi-strain preparations combined 2 to 8 different bacterial subspecies, mostly lactobacilli or bifidobacteria, and used variable lengths of treatments. Overall, more than 50% of trials presented negative outcomes. The majority of the single-strain probiotic trials employing lactobacilli or Saccharomyces were negative, whereas trials employing bifidobacteria showed positive results. ConclusionsThe heterogeneity of the studies of probiotics in IBS questions the value of meta-analyses. The use of different bacterial strains and different mixtures of these strains, as well as different dosages, are the main contributors to this heterogeneity. Current data provides limited evidence for the efficacy of a small number of single-strain probiotics in IBS (mostly bifidobacteria) and

show abstract

“…Several trials have been excluded from this list because of failure to compare with placebo (49) , re-analysis of old data (50) , unclear end points (51) or the use of multiple interventions (52) . Many early studies were small singlecentre trials (53)(54)(55)(56)(57) , although more recently a number of much larger multi-centre trials have been undertaken, reflecting the growing interest in the area (58)(59)(60)(61) .…”

Section: Probiotics In Irritable Bowel Syndrome: Clinical Trialsmentioning

confidence: 99%

Treating irritable bowel syndrome with probiotics: the evidence

2010

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a disorder of chronic abdominal pain, altered bowel habit and abdominal distension. It is the commonest cause of referral to gastroenterologists in the developed world and yet current therapeutic strategies are often unsatisfactory. There is now increasing evidence linking alterations in the gastrointestinal (GI) microbiota and IBS. Changes in faecal and mucosa-associated microbiota, post-infectious IBS, a link with small intestinal bacterial overgrowth and an up-regulation of the GI mucosal immune system all suggest a role for the GI microbiota in the pathogenesis of IBS. Given this evidence, therapeutic alteration of the GI microbiota by probiotic bacteria could be beneficial. The present paper establishes an aetiological framework for the use of probiotics in IBS and comprehensively reviews randomised placebo-controlled trials of probiotics in IBS using multiple electronic databases. It highlights safety concerns over the use of probiotics and attempts to establish guidelines for their use in IBS in both primary and secondary care.Probiotics: Irritable bowel syndrome: Small bowel intestinal overgrowth: Gastrointestinal microbiota

show abstract

The efficacy of ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study

Cited by 166 publications

References 23 publications

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome

Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

Treating irritable bowel syndrome with probiotics: the evidence

Contact Info

Product

Resources

About